Does adverse affect of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer?
Adverse affects of paclitaxel and carboplatin combination chemotherapy are acceptable and manageable in the majority of patients.
This study suggests that p53 might act as a new potential therapeutic target against BSM remodeling in asthmatic patients.